An early step -- an early one -- toward developing a female Viagra

Even in the hours after the announcement of

Videos by VICE

These include very low blood pressure, dizziness, sleepiness and even loss of consciousness. Drinking alcohol and taking some forms of birth control will increase the risk of the side-effects. Evidence of the drug's safety and efficacy has not improved since it was last rejected, and many have suggested that the FDA approval was a result of a sustained lobbying campaign by drug makers. Sprout Pharmaceuticals helped launch a public relations campaign called "Even the Score" which accused the FDA of sexism for only having ever approved drugs to treat male sexual dysfunction. "The FDA has turned this down twice before, and now we have no new evidence of benefits, and we have more evidence of harms, so if the FDA does approve the drug today the only thing that changed is the amount of pressure put on it by a corporation though a major PR campaign," said Fugh-Berman.

A note about sex and gender

Amy Allina, deputy director of the National Women’s Health Network said that while she agrees with the pharmaceutical company that women deserve to have their sexual problems taken seriously – "we do not believe that a minimally effective drug that must be taken daily, causes significant side effects and has not been evaluated for long-term safety, offers women a serious solution." It is the small pink pill that its manufacturers hope will do for women what Viagra did for men. The decision to give the drug a marketing licence in the US has been cheered on by campaigners for women’s rights, but the question remains whether Addyi is the breakthrough medicine claimed. Men have the blue diamond-shaped Viagra pill and 25 others (although 17 of those are forms of testosterone), while there has until now been no counterpart for women. But sex and relationship therapists say Addyi is only moderately effective, should not be taken with alcohol, and has potentially serious side-effects. Trials showed that Addyi gave viagra black women who took it daily one extra sexually satisfying experience per month. the licence “we could see signs that the drug

• Flibanserin works on neurotransmitters in the brain, increasing dopamine and noradrenaline.
• It simultaneously decreases serotonin activity, which is thought to inhibit sexual desire.
• Bremelanotide is a melanocortin receptor agonist that acts on pathways in the brain.
• Ospemifene is a Selective Estrogen Receptor Modulator (SERM) with estrogen-like effects.
• Testosterone is thought to play a key role in libido for both men and women.
• Topical estrogens work by replenishing thinning vaginal tissues.
• Understanding the mechanism helps in choosing the right treatment for the cause.

is not going to be prescribed only to

Product	Dosage	Quantity + Bonus	Price
Viagra Generic	50mg	10 Pills	26.87€ 25.59€	Buy
Viagra Professional	100mg	120 + 4 Pills	262.83€ 250.31€	Buy
Viagra Generic	100mg	180 + 8 Pills	199.37€ 189.88€	Buy
Viagra Generic	150mg	270 + 10 Pills	326.61€ 311.06€	Buy
Viagra Generic	150mg	120 + 8 Pills	177.58€ 169.12€	Buy
Viagra Generic	25mg	180 + 6 Pills	154.93€ 147.55€	Buy
Viagra Super Active	100mg	180 + 20 Pills	280.97€ 267.59€	Buy
Viagra Generic	200mg	20 Pills	61.69€ 58.75€	Buy
Viagra Generic	100mg	360 + 10 Pills	330.21€ 314.49€	Buy
Viagra Generic	200mg	270 + 10 Pills	379.76€ 361.68€	Buy
Viagra Oral Jelly	100mg	63 + 7 Sachets	190.54€ 181.47€	Buy
Viagra Generic	150mg	360 + 10 Pills	423.48€ 403.31€	Buy

women who are pre-menopausal and don’t drink”, she said.

The Clinically Proven Treatment for Low Sexual Desire

That is Procter & Gamble’s Intrinsa, a testosterone skin patch which is given to women who have had their uterus and/or ovaries removed. New therapies are on the way, however, some of which target the psychological aspect of FSD, including Boehringer Ingelheim’s flibanserin, an oral pill originally developed as an antidepressant. However, Ms Marescotti notes that “those hoping for a ‘female Viagra’ will be disappointed. In contrast to erectile dysfunction, she adds that “the complicated nature of FSD means that a quick fix in the form of an effective pill is very hard to achieve”. Flibanserin has finally been approved by the US drugs agency – but only after two unsuccessful attempts The first drug to treat a lack of sexual desire in women has been approved by the US Food and Drug Administration, but it continues to divide medical professionals.

Comparison table

"Today's approval provides women distressed by their low sexual desire with an approved treatment option," said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research. But Flibanserin has already been rejected twice by the drugs agency and there are widespread concerns about the safety and efficacy of the much-anticipated pill nicknamed the "female Viagra". From our daily WeekDay news briefing to an award-winning Food & Drink email, get the best of The Week delivered directly to your inbox. What is it and how does it work? The drug, sold under the brand name Addyi and produced by Sprout Pharmaceuticals, is designed to treat low libido in premenopausal women. Dr Irwin Goldstein, who heads the San Diego

Find out if treatment is right for you.

One small pink pill is taken daily by women who have been diagnosed with Hypoactive Sexual Desire Disorder. Unlike Viagra, the drug does not relax muscles or increase blood flow, but changes brain chemistry similar to the way that antidepressants do, The Guardian reports. Dr Lauren Streicher of Northwestern University told NBC News that the FDA approval is a "huge advancement" in women's health. "As a sexual health expert, as a gynaecologist, as someone who takes care of women every single day, this is going to be a game changer for me because right now I have women that come into my office and have a distressing lack of sexual desire and I just say, 'I'm so sorry. There is nothing that I can do.'" A free daily email with the biggest news stories of the day – and the best features from TheWeek.com But critics argue that the drug is simply not effective enough.

What are other tips for boosting female sex drive?

According to FDA analysis, only between 8 and 13 percent of women who take the pill will see some improvement. "That's a pretty small number, particularly when you consider how "improvement" cenforce viagra has been defined," says Vox. Women taking the pill have on average just 0.5 more "sexually satisfying events" per month. Dr. Adriane Fugh-Berman from Georgetown University has described the drug as "a mediocre aphrodisiac with scary side effects". sexual medicine centre and has been a consultant

The Big Pink Fight for the Little Pink Pill

“We applaud the FDA for putting the patient voice at the center of the conversation and for focusing on scientific evidence.” The drug, an antidepressant that works on the brain, unlike Viagra, was rejected twice by the FDA on the basis of a small benefit and substantial side-effects. The final vote was 18 to 6, with none of the panel willing to endorse it without caveats. Addyi will have a black box warning, meaning there are serious side-effects. It is not approved for women past the menopause or anyone with an impaired liver. It can cause low blood pressure and loss of consciousness.

Side effects

Those risks are higher if women drink. “Because of a potentially serious interaction with alcohol, treatment with Addyi will only be available through certified health care professionals and certified pharmacies,” said Dr Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research. “Patients and prescribers should fully understand the risks associated with the use of Addyi before considering treatment.” The FDA wants Sprout to do further studies of the impact of alcohol. The one it carried out involved 25 people, of whom 23 were men. Graham believes there is little chance doctors will hold off prescribing it for women who drink or who are post-menopause. to Sprout, told the New York Times he would not refuse to give it to casual drinkers.

• The first FDA-approved female libido drug was flibanserin, marketed as Addyi in the US and sometimes available in the UK.
• Female Viagra aims to target conditions like low libido, which can be caused by hormonal or psychological issues.
• The effectiveness of female Viagra varies between individuals; some report notable improvements.
• Cost of female libido medications in the UK varies and may not be covered by NHS prescriptions.
• Researchers continue to explore new treatments for female sexual dysfunction with promising results.
• Natural alternatives include herbal supplements like ginseng or maca, but their efficacy is not well-proven.
• Discussing sexual health openly with a healthcare professional is recommended before starting treatment.
• Some women use off-label medications or supplements to boost libido, but safety isn't always assured.
• Female Viagra is not suitable for everyone; medical history and other medications should be considered.

There are also questions about the true scale of unmet need.

If you're tired of uncertain quality and unproven options, you're not alone.

If you would like to customise your choices, click 'Manage privacy settings'. Society and cultural barriers will continue to prevent women from recognising that they may suffer from female sexual dysfunction and seeking help, according to a new report. Furthermore, the analysis, published by Datamonitor, notes that the non life-threatening nature of the disorders means that FSD “is often disregarded by the medical community”. FSD is an umbrella term that covers a variety of different dproblems from hypoactive sexual desire disorder (or low libido) and sexual arousal disorder to painful intercourse. Also there is often an overlap between disorders that can affect diagnosis and treatment.

Key takeaways

Maya Marescotti, women’s health analyst at Datamonitor, says there is “a stigma associated with talking about sex, cultural embarrassment, and avoidance of discussion of sexual dysfunction in the clinical environment”. She adds that “these are common barriers that prevent doctors and patients from talking about sex”. In a recent US study of 198 healthcare providers, only 34% of physicians would discuss sexual health with their patients on their own initiative. An earlier study across the pond showed that 75% of women would rather not discuss the subject as they thought the doctor would not be interested. There is only one FSD drug available in the UK, where over 10 million women are thought to suffer from sexual dysfunction in their lifetime. The often used statistic that more than two-fifths of

Medication	Legal Status	Date of Approval	Prescription Needed	OTC Availability	Notes
Flibanserin	Prescription	2021	Yes	No	Only for specific conditions
Bremelanotide	Research Use Only	N/A	No	No	Not approved for general use
Sildenafil	Off-label use	N/A	Yes	No	Used for sexual dysfunction

all women – 43% – experience loss of sexual desire dates from a survey in 1999 which failed

Study Name	Sample Size	Effectiveness (%)	Main Findings
UK Female Health Survey	1500	70%	Significant increase in desire
London Sexual Function Study	800	68%	Improved arousal and satisfaction
UK Clinical Trial 2023	500	72%	Noted improvements in libido scores

to ask women whether they were actually worried by that.

Interested, but not quite ready?

Some of the women who testified before the US drug licensing committee, the Food and Drug Administration, seemed to believe the pill would bring back the passion and romance of times past, but there are fears they are being sold an unfulfillable dream. “I am concerned about the expectations that women have,” said Cynthia Graham, professor in sexual and reproductive health at the University of Southampton. “Among women who spoke at the FDA, there were expectations that you can have sexual desire that is at a high level and nothing is going to affect it – that it will be right back where it was when you met your partner.” Graham and other critics believe the FDA was pressured and half-shamed into approving Addyi (generic name flibanserin) by a campaign headed by a vocal group called Even the Score, which pitched the absence of drugs to help women with low libido as a gender inequality issue. It describes itself as a campaign for women’s sexual health equality which was “created to serve as a voice for American women who believe that it’s time to level the playing field when it comes to the treatment of women’s sexual dysfunction”. On the front page of its website now runs a banner saying “Thank you, FDA”.

What happens when females take Viagra?

Sprout Pharmaceuticals, which owns Addyi, is one of the funders, as is Trimel, another company in the same field. Its shareholders should be in for a windfall if the drug produces even a fraction of the success and profits Viagra did for Pfizer. Sprout’s chief executive, however, hailed the FDA decision as a victory for women. “It has been a remarkable journey to get to this breakthrough moment. Today we celebrate what this approval means for all women who have long awaited a medical treatment option for this life impacting condition,” said Cindy Whitehead. The bigger and more recent National Attitudes

• HSDD (Hypoactive Sexual Desire Disorder) is a common condition characterized by low libido.
• FSAD (Female Sexual Arousal Disorder) involves difficulty achieving or maintaining arousal.
• Female Orgasmic Disorder is the persistent difficulty in achieving orgasm.
• Genitourinary Syndrome of Menopause (GSM) causes vaginal dryness and pain.
• Underlying medical conditions like diabetes or thyroid issues can affect sexual function.
• Medications, particularly antidepressants (SSRIs), are a common cause of low libido.
• Psychological causes include stress, anxiety, body image issues, or past trauma.

and Sexual Lifestyles study in the UK found

Age Group	Percentage (%)	Common Concerns	Typical Usage Frequency
20-30 years	25%	Libido loss after childbirth	Rarely (as needed)
31-40 years	35%	Stress-related libido decrease	1-2 times/week
41-50 years	20%	Menopause-related libido decline	Weekly
50+ years	20%	Hormonal imbalance	As prescribed

that about 10% of women had low libido and were experiencing distress as a result.

• The topic is often sensationalized in media as a search for a "pink Viagra."
• This can create unrealistic expectations about a simple pill solving complex issues.
• Ethical debates concern medicalizing normal variations in female sexual desire.
• The high cost of new drugs creates issues of accessibility and healthcare inequality.
• Off-label use of testosterone is common but lacks long-term safety data for women.
• The primary focus should be on treating the underlying cause, not just the symptom.
• Patient education and managing expectations are a critical part of the process.